title: Peripheral vasodilator and cardiac properties of the 1,5-benzothiazepine calcium antagonist analog, TA-3090, in dogs.
abstract: Diltiazem, a 1,5-benzothiazepine, has demonstrated efficacy in the treatment of numerous cardiovascular diseases. TA-3090, a newly synthetized 1,5-benzothiazepine compound was studied in open-chest anesthetized dogs to characterize its hemodynamic properties, to compare it with diltiazem, and finally to correlate hemodynamic properties and plasma level concentrations. Anesthetized open-chest dogs were instrumented with electronic devices and fluid-filled catheters to monitor cardiac, coronary, and peripheral hemodynamic changes. A cumulative intravenous bolus administration of TA-3090 (n = 16) or diltiazem (n = 15) (15, 50, 200, and 400 micrograms/kg) was carried out, and blood samples were taken before and 5 min following each dose administration. Hemodynamic changes were followed for 30 min after each administration, at which time most hemodynamic parameters were back to baseline levels. The results indicate that both TA-3090 and diltiazem elicit slight peripheral and coronary vasodilator properties at low doses (15 and 50 micrograms/kg). With higher dosage, hemodynamic effects were maximal: coronary blood flow increased by 75%, arterial pressure decreased by 25%, and reflex positive inotropic effects were also observed. Heart rate was significantly reduced (10%). Comparison between TA-3090 and diltiazem indicates that both drugs elicit coronary vasodilator selectivity and TA-3090 has a prolonged duration of action compared with that of diltiazem. A straightforward relationship is demonstrated between vasodilator properties and plasma levels of either TA-3090 or diltiazem. Our data suggest that with plasma levels between 40 and 80 ng/mL, significant hemodynamic changes were observed with TA-3090. Changes of heart rate were not correlated with plasma levels.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Département de pharmacologie, Faculté de médecine, Université de Montréal (Québec), Canada.
authors.forename: L
authors.initials: L
authors.lastname: Dumont
authors.forename: M
authors.initials: M
authors.lastname: Derouin
authors.forename: C
authors.initials: C
authors.lastname: Chartrand
authors.forename: P
authors.initials: P
authors.lastname: Archambeault
authors.forename: D
authors.initials: D
authors.lastname: Garceau
authors.forename: G
authors.initials: G
authors.lastname: Caillé
mesh_terms: D000818:Animals; D002121:Calcium Channel Blockers / Q000097:blood / Q000494:pharmacology*; D002316:Cardiotonic Agents / Q000494:pharmacology; D004110:Diltiazem / Q000031:analogs & derivatives* / Q000097:blood / Q000494:pharmacology; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D006321:Heart / Q000187:drug effects*; D006439:Hemodynamics / Q000187:drug effects*; D014665:Vasodilator Agents / Q000494:pharmacology
chemical_list: D002121:Calcium Channel Blockers; D002316:Cardiotonic Agents; D014665:Vasodilator Agents; C056595:clentiazem; D004110:Diltiazem